464913-11-9

Basic information

• Product Name: 3-AMINO-2-HYDROXY-N,N-DIMETHYLBENZAMIDE
• Synonyms: 3-AMINO-2-HYDROXY-N,N-DIMETHYLBENZAMIDE;3-aMino-N,N-diMethylsalicylaMide
• CAS NO: 464913-11-9
• Molecular Formula: C₉H₁₂N₂O₂
• Molecular Weight: 180.20378
• Mol File: 464913-11-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 3-AMINO-2-HYDROXY-N,N-DIMETHYLBENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-2-HYDROXY-N,N-DIMETHYLBENZAMIDE(464913-11-9)
• EPA Substance Registry System: 3-AMINO-2-HYDROXY-N,N-DIMETHYLBENZAMIDE(464913-11-9)

Safety Data

• Hazardous Substances Data: 464913-11-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-AMINO-2-HYDROXY-N,N-DIMETHYLBENZAMIDE is used as a reagent in organic synthesis for its ability to participate in various chemical reactions, contributing to the formation of a wide range of organic compounds.
Used in Pharmaceutical and Medicinal Chemistry:
Due to its structural features, 3-AMINO-2-HYDROXY-N,N-DIMETHYLBENZAMIDE may be employed in the development of pharmaceuticals and medicines. Its potential applications in this field could include the synthesis of new drug candidates or the modification of existing ones to improve their efficacy and safety.
Used in Chemical Research:
In the field of chemical research, 3-AMINO-2-HYDROXY-N,N-DIMETHYLBENZAMIDE can be utilized to study the properties of amides and their derivatives, as well as to explore new reaction mechanisms and synthetic pathways.
Used in Chemical Education:
3-AMINO-2-HYDROXY-N,N-DIMETHYLBENZAMIDE can also serve as a teaching aid in chemical education, helping students understand the properties and reactions of amides and their derivatives, and providing practical experience in handling and synthesizing such compounds.

Upstream product

• 66952-65-6 2-hydroxy-N,N-dimethyl-3-nitrobenzamide 
• 473731-67-8 5-bromo-2-hydroxy-3-nitro-N,N-dimethylbenzamide 
• 35748-36-8 2-hydroxy-3-nitrobenzoyl chloride 
• 85-38-1 3-nitrosalicylic acid 

Downstream Products

• 473732-10-4 2-hydroxy-3-(2-methoxy-3,4-dioxo-cyclobut-1-enylamino)-N,N-dimethyl-benzamide 
• 464913-33-5 3-((2-ethoxy-3,4-dioxocyclobut-1-en-1-yl)amino)-2-hydroxy-N,N-dimethylbenzamide 
• 681509-60-4 C₁₃H₁₆N₄O₄S 
• 473727-83-2 squaramide 

Relevant articles and documents

Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists

A novel series of 3,4-diaminocyclobut-3-ene-1,2-diones was prepared and found to show potent inhibitory activity of CXCR2 binding and IL-8-mediated chemotaxis of a CXCR2-expressing cell line. Microsome stability and Caco2 studies were subsequently used to

Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists

Chemokine receptor 2 (CXCR2) is the receptor of glutamic acid–leucine–arginine sequence-contained chemokines CXCs (ELR+ CXCs). In recent years, CXCR2-target treatment strategy has come a long way in cancer therapy. CXCR2 antagonists could block

Bicyclo[2.2.1]heptane containing: N, N ′-diarylsquaramide CXCR2 selective antagonists as anti-cancer metastasis agents

CXCR1 and CXCR2 are CXC chemokine receptors (CXCRs), corresponding to cytokines of the CXC chemokine family. CXCR2 was found to be 77% homologous to CXCR1. Antagonism of the chemokine receptor CXCR2 has been proposed as a new strategy for the treatment of

NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds corresponding to general formula (I) are disclosed. Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated diseases.

NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are described that correspond to general formula (I). Also described, are pharmaceutical compositions that include these compounds and methods of using these compounds and compositions for the tr

DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES

Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are disclosed that are represented by general formula (I). Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the

NOVEL HYDRAZINO-CYCLOBUT-3-ENE-1, 2-DIONE DERIVATIVES AS CXCR2 ANTAGONISTS

The present invention relates to novel hydrazino-cyclobut-3-ene-1,2-dione compounds of Formula (I) as selective CXCR2 antagonists, pharmaceutical compositions containing the novel compounds, as well as methods for treating or preventing chemokine mediated

3, 4-DI-SUBSTITUTED CYCLOBUTENE- 1, 2 -DIONES AS CXCR2 RECEPTOR ANTAGONISTS

The present invention relates to compounds of formula (I) wherein R1, R2, Ar, p, R4 and R5 are as defined herein, which are useful for creating diseases which respond to CXCR2 receptor mediators. Pharmaceutical

PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS

This application discloses a novel process for the preparation of 1.2 - substituted 3, 4 - dioxo - 1 - cyclobutene compounds of formula (A), which have utility, for example, in the treatment of CXC chemokine -mediated diseases, and intermediates useful in the synthesis thereof.

3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel cyclobutenedione Compounds comprising a cycloclobutenedione ring, a substituted phenyl ring, and a -CH(C2H5)-furan moiety. The phenyl ring and the -CH(C2H5)-furan moiety are each bound to the